Abstract:[Objective] To investigate the clinical effect of ropivacaine concentration used in lumbar plexus block during total hip arthroplasty (THA). [Methods] From January 2022 to August 2023, 100 patients undergoing initial unilateral THA under general anesthesia combined with lumbar plexus block were included in this study. The patients were randomly divided into three groups by coin tossing method, and received lumbar plexus block before operation. Among them, 32 patients received 0.25% ropivacaine, 34 patients received 0.30% ropivacaine, and 34 patients received 0.35% ropivacaine. The documents regarding perioperative period were compared among the three groups. [Results] There were no significant differences in operation time, intraoperative blood loss, recovery time, extubation time and getting out of bed time among the three groups (P>0.05). The 0.25% group had mean arterial pressure (mmHg) [(98.8±1.2), (96.4±3.4), (90.4± 4.8), (84.8±2.5), P=0.208] and heart rate (b/min) [(78.5±6.0), (77.4±6.9), (74.7±7.3), (75.2±6.3), P=0.076] remained unchanged significantly during different time points intraoperatively, whereas the 0.30% group and 0.35% group got significant changes in mean arterial pressure and heart rate (P<0.05). However, there was no significant difference in the incidence of adverse reactions among the three groups (P>0.05). In terms of postoperative pain, there were no statistically significant differences in postoperative VAS score, time of first additional analgesia, number of analgesic pump compression, and frequency of vasoactive drug use among the three groups (P>0.05). [Conclusion] Low concentration of ropivacaine is more stable in hemodynamic treatment of lumbar plexus block during THA, which is not significantly different in analgesic effect compared with higher concentration of ropivacaine.